Protocol Ledger

NCT07288034 · Phase II · RECRUITING

Immunotherapy Biomarkers to Predict First-line PD(L)1-based Immunotherapy Response and Selection of Second-line Treatment in Stage IIIB-IV Non-small Cell Lung Cancer, IMMUNO-BIOMAP Trial

Interventional Phase II clinical trial protocol NCT07288034 sponsored by City of Hope in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2026-05-01 Enrollment: 535 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT07288034
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)535 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT07288034
Protocol FieldVerified Registry Value
NCT IdentifierNCT07288034
Consolidated Lead SponsorCity of Hope
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II
Overall Recruitment StatusRECRUITING
Registered Enrollment535 participants (ESTIMATED)
Registered Start Date2026-05-01
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT07288034
Hospital Research SiteLocationSite Profile
City of Hope National Medical CenterDuarte, CAOpen Hospital Dossier ->
City of Hope Orange CountyIrvine, CAOpen Hospital Dossier ->
City of Hope (Lancaster)Lancaster, CAOpen Hospital Dossier ->
City of Hope (Long Beach)Long Beach, CAOpen Hospital Dossier ->

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for City of Hope across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI